TISSUE REGENIX GROUP PLC — Share Issue/Capital Change 2015

Nov 5, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7625E

Tissue Regenix Group PLC

05 November 2015

Tissue Regenix Group Plc

Issue of equity and total voting rights

YORK, 5 November 2015 - Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "the Company"), the regenerative medical devices company, announces that it has today issued and allotted 444,508 ordinary shares of 0.5p each in the Company, following an exercise of options which were granted under the Company's unapproved share option scheme.

The 444,508 new ordinary shares will rank pari passu with the existing ordinary shares and application will be made for these new ordinary shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00 a.m. on 11 November 2015.

Total Voting Rights

Following the issue of the 444,508 new ordinary shares, the Company will have a total of 760,124,264 ordinary shares of 0.5p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

For Further Information

Tissue Regenix Group Plc:                                                           +44 19 0456 7609

Caitlin Pearson

Corporate Communications Officer

c.pearson@tissueregenix.com

Jefferies International Ltd:                                                         +44 20 7029 8000

Simon Hardy

Harry Nicholas

Tulchan Communications:          

James Macey White                                                                       +44 207 353 4200

Matt Low

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL® technology platform.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCEAKFSEDNSFFF